Wolfe Research analyst Doug Schenkel downgraded Myriad Genetics (MYGN) to Peer Perform from Outperform.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- China announces stimulus measures, Disney reports Q2 beat: Morning Buzz
- Myriad Genetics price target lowered to $18 from $29 at Craig-Hallum
- Myriad Genetics price target lowered to $7 from $16 at UBS
- Myriad Genetics price target lowered to $10 from $19 at Raymond James
- Wells downgrades Myriad Genetics, sees ‘show-me story’ after miss
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue